NASDAQ · RTSN

Retension Pharmaceuticals financials

$11.30−0.53%

Close Nov 2, 2026 · split-adjusted

Retension Pharmaceuticals has no quarterly financial statements on file. Funds and some foreign issuers do not file them.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology